SARS-CoV-2 and COVID-19¶
Chapter 205 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- SARS-CoV-2 is a Betacoronavirus causing COVID-19, with high transmissibility (R0 ~6) and severe outcomes in older adults and immunocompromised patients.
- Transmission occurs via respiratory droplets, aerosols, and fomites; airborne spread over long distances is unlikely.
- Key risk factors include advanced age (>65 years), obesity, diabetes, cardiovascular disease, and immunosuppression.
- Management includes antivirals (nirmatrelvir-ritonavir, remdesivir), corticosteroids (dexamethasone), and thromboprophylaxis for hospitalized patients.
- Vaccination remains the cornerstone of prevention, with updated mRNA vaccines targeting emerging variants (e.g., BA.5, XBB, KP.2).
1. DEFINITION & OVERVIEW¶
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is a novel Betacoronavirus that emerged in late 2019, causing the global pandemic of COVID-19. It is an enveloped, positive-sense RNA virus with a single-stranded RNA genome of ~30,000 nucleotides. The virus primarily infects the respiratory tract but can cause systemic complications. The spike (S) protein mediates viral entry via binding to the angiotensin-converting enzyme 2 (ACE2) receptor.
Classification of SARS-CoV-2 Variants¶
| Variant Category | Definition | Examples |
|---|---|---|
| VUMs (Variants Under Monitoring) | Low risk of impact on diagnostics, public health, or vaccine efficacy | Alpha, Gamma |
| VOIs (Variants of Interest) | Potential risk of increased transmissibility or disease severity | Lambda, Mu |
| VOCs (Variants of Concern) | Significant impact on diagnostics, public health, or vaccine efficacy | Delta, Omicron |
1.1 Pathogenesis¶
SARS-CoV-2 enters host cells via ACE2 receptor binding, followed by endosomal entry and replication. The S protein is cleaved by TMPRSS2, enabling membrane fusion. Viral replication leads to cytopathic effects and immune activation, resulting in cytokine storm and hyperinflammation in severe cases.
1.2 Clinical Spectrum¶
Clinical manifestations range from asymptomatic infection to severe pneumonia, acute respiratory distress syndrome (ARDS), and multiorgan failure. Long COVID (chronic symptoms persisting >3 months) includes fatigue, cognitive deficits, and persistent respiratory symptoms.
2. EPIDEMIOLOGY¶
SARS-CoV-2 originated in a bat reservoir, with zoonotic transmission to humans likely via intermediate hosts (e.g., pangolins). The virus spread globally, with the WHO declaring a pandemic in March 2020. As of September 2024, >700 million cases and >7 million deaths were reported worldwide. Risk factors include advanced age (>65 years), obesity, diabetes, cardiovascular disease, and immunosuppression.
2.1 Demographics¶
Over 95% of deaths occur in individuals >45 years, with >80% of deaths in those >65 years. Racial/ethnic minorities and individuals with disabilities face higher risks due to social determinants of health.
2.2 Transmission¶
Primary transmission occurs via respiratory droplets and aerosols in enclosed spaces. Fomite transmission is possible but less common. Outdoor transmission is less frequent.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
SARS-CoV-2 is a Betacoronavirus with a single-stranded RNA genome. The spike protein mediates ACE2 receptor binding, enabling viral entry. The virus replicates in the respiratory tract, causing epithelial damage and immune activation. Hyperinflammation, cytokine storm, and coagulopathy contribute to severe disease.
3.1 Viral Replication¶
The virus uses RNA-dependent RNA polymerase (RdRp) for replication, leading to frequent mutations and emergence of variants. The S protein is primed by TMPRSS2 for membrane fusion.
3.2 Immune Response¶
Early innate immune response includes interferon production. Adaptive immunity involves T cells and B cells. Excessive inflammatory cytokines (e.g., IL-6, TNF- α ) drive tissue damage and multiorgan failure.
4. CLINICAL FEATURES¶
Symptoms include fever, cough, myalgia, dyspnea, and anosmia. Severe disease presents with ARDS, sepsis, and multiorgan failure. Long-term complications include post-COVID syndrome (fatigue, cognitive deficits) and increased risk of cardiovascular events.
4.1 Mild Disease¶
Mild symptoms (e.g., fever, cough) without pneumonia. Most patients recover within 2 weeks.
4.2 Severe Disease¶
Pneumonia, ARDS, hypoxemia, and multiorgan failure. Requires oxygen therapy, mechanical ventilation, or ICU care.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include influenza, bacterial pneumonia, tuberculosis, and other viral respiratory infections (e.g., RSV, adenovirus). Clinical features and imaging (e.g., chest X-ray/CT) aid differentiation.
5.1 Common Mimics¶
Influenza: Similar symptoms but shorter duration. Bacterial pneumonia: More localized chest pain and purulent sputum. Tuberculosis: Chronic cough and weight loss.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis is confirmed by RT-PCR (nasopharyngeal swab) or antigen tests. Chest imaging (X-ray/CT) shows ground-glass opacities. Laboratory findings include lymphopenia, elevated inflammatory markers, and coagulopathy.
6.1 Diagnostic Tests¶
RT-PCR: Gold standard for viral detection. Antigen tests: Rapid but less sensitive. Serology: Detects IgM/IgG antibodies for past infection.
6.2 Imaging¶
Chest X-ray: May show bilateral infiltrates. CT scan: More sensitive for detecting ground-glass opacities and consolidation.
7. MANAGEMENT & TREATMENT¶
Outpatient management includes antivirals (nirmatrelvir-ritonavir), corticosteroids (dexamethasone), and supportive care. Inpatient care involves oxygen therapy, mechanical ventilation, and immunomodulatory agents (tocilizumab, baricitinib).
Outpatient vs. Inpatient Management Criteria¶
| Criteria | Outpatient | Inpatient |
|---|---|---|
| Oxygen saturation | ‡94% on room air | <94% or >30 breaths/min |
| Lung infiltrates | £50% lung fields | >50% lung fields |
| Comorbidities | Stable with no exacerbation | Severe comorbidities (e.g., COPD, heart failure) |
7.1 Antiviral Therapy¶
Nirmatrelvir-ritonavir: Dosed as 300 mg/100 mg twice daily for 5 days. Remdesivir: IV infusion over 3 days. Molnupiravir: EUA for specific populations with mutagenic risks.
7.2 Immunomodulation¶
Dexamethasone: Reduces mortality in severe cases. Tocilizumab: Blocks IL-6 signaling in cytokine storm. Baricitinib: JAK inhibitor for cytokine suppression.
8. PROGNOSIS & COMPLICATIONS¶
Mortality is highest in older adults and those with comorbidities. Complications include ARDS, sepsis, thromboembolism, and long-term sequelae (e.g., post-COVID syndrome). Survivors may experience persistent fatigue, cognitive deficits, and increased cardiovascular risk.
8.1 Mortality¶
Over 95% of deaths occur in individuals >45 years. Mortality is 80% in those >65 years. Risk factors include obesity, diabetes, and immunosuppression.
8.2 Long-Term Effects¶
Long COVID: Persistent symptoms ( ≥ 3 months) including fatigue, dyspnea, and cognitive dysfunction. Increased risk of cardiovascular events and mental health disorders.
9. SPECIAL CONSIDERATIONS¶
Pregnant women face higher risks of severe disease and adverse outcomes. Children have lower risk of severe disease but may develop MIS-C (multisystem inflammatory syndrome). Elderly patients require careful monitoring for comorbidities and frailty.
9.1 Pregnancy¶
Higher risk of ICU admission and maternal mortality. Vertical transmission is possible but rare. Antenatal corticosteroids may reduce neonatal complications.
9.2 Pediatrics¶
MIS-C (pediatric multisystem inflammatory syndrome) presents with fever, rash, and multiorgan involvement. Vaccination is recommended for children ≥ 12 years.
10. KEY POINTS & CLINICAL PEARLS¶
- Vaccination remains the most effective prevention strategy. 2. Early antiviral therapy (within 5 days of symptoms) reduces severe outcomes. 3. Dexamethasone improves survival in severe cases. 4. Long COVID requires multidisciplinary management. 5. Updated vaccines are critical to address emerging variants.